Use of magnetic resonance imaging contrast agents to detect transplanted liver cells

Topics in Magnetic Resonance Imaging

Volumn 20, Issue 2, 2009, Pages 113-120

  Puppi, Juliana ^a   Modo, Michel ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cell transplant; Cellular imaging; Contrast agent; Hepatocytes; Liver; MRI; Stem cells

Indexed keywords

FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOXETIC ACID; IRON OXIDE; MANGAFODIPIR; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

CYTOTOXICITY; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO;

CELLS, CULTURED; CONTRAST MEDIA; HEPATOCYTES; HUMANS; IMAGE ENHANCEMENT; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; SURGERY, COMPUTER-ASSISTED;

EID: 74249105908     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e3181c0dfe4     Document Type: Review

References (94)

1. Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis. 1999;19:39-48.
2. Allen KJ, Soriano HE. Liver cell transplantation: the road to clinical application. J Lab Clin Med. 2001;138:298-312.
3. Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis. 2006;29:431-435.
4. Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver diseases. Pediatr Transplant. 2008;12:6-13.
5. Mas VR, Maluf DG, Thompson M, et al. Engraftment measurement in human liver tissue after liver cell transplantation by short tandem repeats analysis. Cell Transplant. 2004;13:231-236.
6. Stephenne X, Najimi M, Sibille C, et al. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology. 2006;130: 1317-1323.
7. Wang LJ, Chen YM, George D, et al. Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences. Liver Transpl. 2002;8:822-828.
8. Modo M. Noninvasive imaging of transplanted cells. Curr Opin Organ Transplant. 2008;13:654-658.
9. Gupta S, Vasa SR, Rajvanshi P, et al. Analysis of hepatocyte distribution and survival in vascular beds with cells marked by 99mTC or endogenous dipeptidyl peptidase IV activity. Cell Transplant. 1997;6:377-386.
10. Bohnen NI, Charron M, Reyes J, et al. Use of indium-111-labeled hepatocytes to determine the biodistribution of transplanted hepatocytes through portal vein infusion. Clin Nucl Med. 2000;25:447-450.
11. Modo M, Hoehn M, Bulte JW. Cellular MR imaging. Mol Imaging. 2005;4:143-164.
12. Clement O, Siauve N, Lewin M, et al. Contrast agents in magnetic resonance imaging of the liver: present and future. Biomed Pharmacother. 1998;52:51-58.
13. Frangioni JV, Hajjar RJ. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation. 2004;110:3378-3383.
14. Karabulut N, Elmas N. Contrast agents used in MR imaging of the liver. Diagn Interv Radiol. 2006;12:22-30.
15. Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. European radiology. 2003;13: 2688-2698.
16. Liou J, Lee JK, Borrello JA, et al. Differentiation of hepatomas from nonhepatomatous masses: use of MnDPDP-enhanced MR images. Magn Reson Imaging. 1994;12:71-79.
17. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14:559-578.
18. Grazioli L, Morana G, Kirchin MA, et al. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison. J Magn Reson Imaging. 2003;17:593-602.
19. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990;175: 494-498.
20. Seneterre E, Weissleder R, Jaramillo D, et al. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. Radiology. 1991;179: 529-533.
21. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319-2331.
22. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta. 1986;881: 307-313.
23. Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004;39:56-63.
24. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis. 2005;178:67-73.
25. Rogers WJ, Meyer CH, Kramer CM. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med. 2006;3: 554-562.
26. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn Reson Med. 2005;53:329-338.
27. Reimer P, Bader A, Weissleder R. Preclinical assessment of hepatocyte-targeted MR contrast agents in stable human liver cell cultures. J Magn Reson Imaging. 1998;8:687-689.
28. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17:484-499.
29. Rogers JM, Jung CW, Lewis J, et al. Use of USPIO-induced magnetic susceptibility artifacts to identify sentinel lymph nodes and lymphatic drainage patterns. I. Dependence of artifact size with subcutaneous Combidex dose in rats. Magn Reson Imaging. 1998;16:917-923.
30. Rausch M, Hiestand P, Baumann D, et al. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med. 2003;50:309-314.
31. Saleh A, Schroeter M, Jonkmanns C, et al. In vivo MRI of brain inflammation in human ischaemic stroke. Brain. 2004;127(pt 7): 1670-1677.
32. Hauger O, Delalande C, Deminiere C, et al. Nephrotoxic nephritis and obstructive nephropathy: evaluation with MR imaging enhanced with ultrasmall superparamagnetic iron oxide-preliminary findings in a rat model. Radiology. 2000;217:819-826.
33. Zhang Y, Dodd SJ, Hendrich KS, et al. Magnetic resonance imaging detection of rat renal transplant rejection by monitoring macrophage infiltration. Kidney Int. 2000;58:1300-1310.
34. Muhler A, Freise CE, Kuwatsuru R, et al. Acute liver rejection: evaluation with cell-directed MR contrast agents in a rat transplantation model. Radiology. 1993;186:139-146.
35. Beckmann N, Hof RP, Rudin M. The role of magnetic resonance imaging and spectroscopy in transplantation: from animal models to man. NMR Biomed. 2000;13:329-348.
36. Briley-Saebo K, Bjornerud A, Grant D, et al. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 2004;316:315-323.
37. Balci N, Erturk S. Cellular MR imaging of the liver using contrast agents. In: Modo M, Bulte J, eds. Molecular and Cellular MR Imaging. Boca Raton, FL: CRC Press; 2007:247-258.
38. Modo M, Meade TJ, Mitry RR. Liver cell labelling with MRI contrast agents. In: Dhawan A, Hughes RD, eds. Hepatocyte Transplantation. New York, NY: Humana Press; 2009:207-219.
39. Josephson L, Kircher MF, Mahmood U, et al. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem. 2002;13:554-560.
40. Modo M, Mellodew K, Cash D, et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. NeuroImage. 2004;21:311-317.
41. Biancone L, Crich SG, Cantaluppi V, et al. Magnetic resonance imaging of gadolinium-labeled pancreatic islets for experimental transplantation. NMR Biomed. 2007;20:40-48.
42. Evgenov NV, Medarova Z, Pratt J, et al. In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes. 2006;55: 2419-2428.
43. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23:1407-1413.
44. Sun R, Dittrich J, Le-Huu M, et al. Physical and biological characterization of superparamagnetic iron oxide- and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison. Investigative radiology. 2005;40:504-513.
45. Fleige G, Seeberger F, Laux D, et al. In vitro characterization of two different ultrasmall iron oxide particles for magnetic resonance cell tracking. Invest Radiol. 2002;37:482-488.
46. Josephson L, Tung CH, Moore A, et al. High-efficiency intracellular magnetic labeling with novel superparamagneticYTat peptide conjugates. Bioconjug Chem. 1999;10:186-191.
47. Morgul MH, Raschzok N, Schwartlander R, et al. Tracking of primary human hepatocytes with clinical MRI: initial results with Tat-peptide modified superparamagnetic iron oxide particles. Int J Artif Organs. 2008;31:252-257.
48. Bulte JW, Zhang S, Van Gelderen P, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A. 1999;96:15256-15261.
49. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 2001;19:1141-1147.
50. Wilhelm C, Billotey C, Roger J, et al. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials. 2003;24:1001-1011.
51. Luciani A, Parouchev A, Smirnov P, et al. In vivo imaging of transplanted hepatocytes with a 1.5-T clinical MRI systemVinitial experience in mice. Eur Radiol. 2008;18:59-69.
52. Kalish H, Arbab AS, Miller BR, et al. Combination of transfection agents and magnetic resonance contrast agents for cellular imaging: relationship between relaxivities, electrostatic forces, and chemical composition. Magn Reson Med. 2003;50:275-282.
53. Arbab AS, Bashaw LA, Miller BR, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology. 2003;229:838-846.
54. van den Bos EJ, Wagner A, Mahrholdt H, et al. Improved efficacy of stem cell labeling for magnetic resonance imaging studies by the use of cationic liposomes. Cell Transplant. 2003;12:743-756.
55. Arbab AS, Yocum GT, Wilson LB, et al. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging. 2004;3:24-32.
56. Matuszewski L, Persigehl T, Wall A, et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005;235: 155-161.
57. Arbab AS, Yocum GT, Kalish H, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood. 2004;104:1217-1223.
58. Walczak P, Kedziorek DA, Gilad AA, et al. Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med. 2005;54: 769-774.
59. Shapiro EM, Sharer K, Skrtic S, et al. In vivo detection of single cells by MRI. Magn Reson Med. 2006;55:242-249.
60. Williams JB, Ye Q, Hitchens TK, et al. MRI detection of macrophages labeled using micrometer-sized iron oxide particles. J Magn Reson Imaging. 2007;25:1210-1218.
61. Raschzok N, Morgul MH, Pinkernelle J, et al. Imaging of primary human hepatocytes performed with micron-sized iron oxide particles and clinical magnetic resonance tomography. J Cell Mol Med. 2008; 12:1384-1394.
62. Muller K, Skepper JN, Posfai M, et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials. 2007;28: 1629-1642.
63. Guzman R, Uchida N, Bliss TM, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci U S A. 2007;104:10211-10216.
64. Kostura L, Kraitchman DL, Mackay AM, et al. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR in biomedicine. 2004;17:513-517.
65. Berry CC, Wells S, Charles S, et al. Cell response to dextran-derivatised iron oxide nanoparticles post internalisation. Biomaterials. 2004;25: 5405-5413.
66. Pisanic TR 2nd, Blackwell JD, Shubayev VI, et al. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials. 2007;28:2572-2581.
67. Bos C, Delmas Y, Desmouliere A, et al. In vivo MR imaging of intravascularly injected magnetically labeled mesenchymal stem cells in rat kidney and liver. Radiology. 2004;233:781-789.
68. Hussain SM, Hess KL, Gearhart JM, et al. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro. 2005;19: 975-983.
69. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol. 2006;41:332-338.
70. Brekke C, Williams SC, Price J, et al. Cellular multiparametric MRI of neural stem cell therapy in a rat glioma model. NeuroImage. 2007; 37:769-782.
71. Brekke C, Morgan SC, Lowe AS, et al. The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry. NMR Biomed. 2007;20:77-89.
72. Modo M, Beech JS, Meade TJ, et al. A chronic 1 year assessment of MRI contrast agentYlabelled neural stem cell transplants in stroke. NeuroImage. 2008.
73. Chrysochou C, Buckley DL, Dark P, et al. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging. 2009;29:887-894.
74. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng. 2008;10:391-411.
75. Zhang S, Winter P, Wu K, et al. A novel europium(III)-based MRI contrast agent. J Am Chem Soc. 2001;123:1517-1518.
76. Zhang S, Merritt M, Woessner DE, et al. PARACEST agents: modulating MRI contrast via water proton exchange. Acc Chem Res. 2003;36:783-790.
77. Snoussi K, Bulte JW, Gueron M, et al. Sensitive CEST agents based on nucleic acid imino proton exchange: detection of poly(rU) and of a dendrimer-poly(rU) model for nucleic acid delivery and pharmacology. Magn Reson Med. 2003;49:998-1005.
78. Koretsky AP, Brosnan MJ, Chen LH, et al. NMR detection of creatine kinase expressed in liver of transgenic mice: determination of free ADP levels. Proc Natl Acad Sci U S A. 1990;87:3112-3116.
79. Landis CS, Yamanouchi K, Zhou H, et al. Noninvasive evaluation of liver repopulation by transplanted hepatocytes using 31P MRS imaging in mice. Hepatology. 2006;44:1250-1258.
80. Walter G, Barton ER, Sweeney HL. Noninvasive measurement of gene expression in skeletal muscle. Proc Natl Acad Sci U S A. 2000;97: 5151-5155.
81. Alfke H, Stoppler H, Nocken F, et al. In vitro MR imaging of regulated gene expression. Radiology. 2003;228:488-492.
82. Gilad AA, Winnard PT Jr, Van Zijl PC, et al. Developing MR reporter genes: promises and pitfalls. NMR Biomed. 2007;20:275-290.
83. Cohen B, Dafni H, Meir G, et al. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia. 2005;7:109-117.
84. Genove G, DeMarco U, Xu H, et al. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med. 2005;11:450-454.
85. Deans AE, Wadghiri YZ, Bernas LM, et al. Cellular MRI contrast via coexpression of transferrin receptor and ferritin. Magn Reson Med. 2006;56:51-59.
86. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol. 2000;18:321-325.
87. Ju S, Teng GJ, Lu H, et al. In vivo MR tracking of mesenchymal stem cells in rat liver after intrasplenic transplantation. Radiology. 2007; 245:206-215.
88. Cai J, Zhang X, Wang X, et al. In vivo MR imaging of magnetically labeled mesenchymal stem cells transplanted into rat liver through hepatic arterial injection. Contrast Media Mol Imaging. 2008;3: 61-66.
89. Choi D, Kim JH, Lim M, et al. Hepatocyte-like cells from human mesenchymal stem cells engrafted in regenerating rat liver tracked with in vivo magnetic resonance imaging. Tissue Eng Part C Methods. 2008;14:15-23.
90. Berkova Z, Jirak D, Zacharovova K, et al. Labeling of pancreatic islets with iron oxide nanoparticles for in vivo detection with magnetic resonance. Transplantation. 2008;85:155-159.
91. Jirak D, Kriz J, Strzelecki M, et al. Monitoring the survival of islet transplants by MRI using a novel technique for their automated detection and quantification. MAGMA. 2009;22:257-265.
92. Koblas T, Girman P, Berkova Z, et al. Magnetic resonance imaging of intrahepatically transplanted islets using paramagnetic beads. Transplant Proc. 2005;37:3493-3495.
93. Kriz J, Jirak D, White D, et al. Magnetic resonance imaging of pancreatic islets transplanted into the right liver lobes of diabetic mice. Transplant Proc. 2008;40:444-448.
94. Toso C, Vallee JP, Morel P, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant. 2008;8:701-706.